Use of Modafinil in the Treatment of Tinnitus

Inclusion Criteria: * The diagnosis of tinnitus should be established by subject through exam and history performed by study physician in Ear, Nose and Throat (ENT) clinic. * Subjects will be age 20 or older. * Subjects should have tinnitus symptoms severe enough to seek medical attention. * Subjects will have been seen in the Hearing and Balance Center at University of Arkansas for Medical Sciences (UAMS). * Subjects will have had an audiogram. * Signed informed consent. * Women of childbearing potential must have a negative pregnancy test at screening and before being prescribed the study drug. * Peripheral neuropathy. * Hematologic (minimal values) at screening Absolute neutrophil count \> 1,500 mm\^3 Hemoglobin \> 8.0 g/dl Platelet count \> 100,000 mm\^3 Exclusion Criteria: Disease-Specific Concerns * Subjects who have locally advanced breast cancer with skin ulceration will be excluded from this study due to the risk of worsening ulcers and healing difficulties * Stage IV breast cancer * Inflammatory breast cancer General Medical Concerns * Subjects with Echo Cardiogram performance status 2, 3, and 4 are not eligible for this study * Allergy to any component of the treatment regimen * Women who are breast feeding * Pregnancy or refusal to use effective contraception while participating in this study * Inability to comply with study and/or follow-up procedures * Subjects with secondary malignancy other than superficial skin cancer (squamous cell carcinoma and basal cell carcinoma of the skin) should be excluded Bevacizumab-Specific Concerns * Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study * Blood pressure of \> 150/100 mmHg. Essential hypertension well controlled with anti hypertensive is not an exclusion criterion * Unstable angina * New York Heart Association (NYHA) Grade II or greater congestive heart failure (see Appendix D) * History of myocardial infarction within 6 months * History of stroke within 6 months * Clinically significant peripheral vascular disease * Evidence of bleeding diathesis or coagulopathy * Presence of central nervous system or brain metastases * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study * Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to Day 0 * Pregnant (positive pregnancy test) or lactating * Urine protein: creatinine ratio \>1.0 at screening * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0 * Serious, non-healing wound, ulcer, or bone fracture